Wegovy and Ozempic, side-by-side A few caveats about the drugs follow, but keep in mind with the marketplace driving much of the thinking, and clinical experience evolving, there may be changes in store: Wegovy is FDA-approved for chronic weight loss management in adults 18 years of age or older with a BMI of 30 or BMI 27 and at least one medical condition related to obesity (e.g., diabetes, hypertension, etc.)
Some describe microdosing as helpful during transitions, such as restarting after a break or adjusting due to side effects
It also suggests that monotreme GLP-1 peptides might promote unique, as yet unknown functions through the montreme GLP-1Rs
These populations already face elevated bone loss risk, and adding GLP-1 therapy without calcium and vitamin D supplementation multiplies that risk substantially
Finley says she still had to put in a lot of work to get healthy
Many patients experience modest weight rebound (2 to 5 pounds) during a 2 to 4 week medication pause, though individual responses vary